Neurotoxicity of Carbapenem Antibacterials
| Autor: | S R Norrby |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Carbapenem
Imipenem medicine.drug_class Cephalosporin Antibiotics Pharmacology Toxicology Meropenem Receptors GABA Seizures polycyclic compounds Animals Humans Medicine Pharmacology (medical) Child Antibacterial agent Cilastatin business.industry Neurotoxicity biochemical phenomena metabolism and nutrition bacterial infections and mycoses medicine.disease Carbapenems Thienamycins business medicine.drug |
| Zdroj: | Drug Safety. 15:87-90 |
| ISSN: | 0114-5916 |
| DOI: | 10.2165/00002018-199615020-00001 |
| Popis: | Similar to other beta-lactam antibacterials, carbapenems have a neurotoxic potential that seems to be higher than that of the penicillins and cephalosporins. Seizures have been reported in several large studies of patients treated with imipenem/cilastatin. However, it seems clear that the main factor increasing the risk of neurotoxicity with imipenem/cilastatin is administration of excessive dosages relative to bodyweight and/or renal function. If the manufacturer's dosage recommendations are followed, the risk of seizures in patients receiving this combination is minimal. With meropenem, a newly registered carbapenem, the safety margin with respect to neurotoxic reactions has been increased compared with imipenem and meropenem can be used at higher doses than imipenem/cilastatin. Since the neurotoxicity of beta-lactam antibacterials seems to be caused by an interaction with gamma-aminobutyric acid (GABA) receptors, other drugs with a similar mechanism of action, such as fluoroquinolone antibacterials, should be used with caution when combined with carbapenems. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink